Vulnerable premature babies needing extra protection against RSV will receive a long-lasting single injection of nirsevimab, ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Thousands of premature babies in the UK can now be protected against a common winter virus which can cause a dangerous lung ...

Like nirsevimab, it’s an antibody that can reduce infections with the virus—but unlike nirsevimab, which is just a single shot, palivzumab requires monthly injections throughout the RSV season.

Experts say the drug will give thousands of vulnerable infants “their own suit of armour” for their first winter ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

A single, long-lasting jab that offers a “protective bubble” to premature babies from a common virus is set to be rolled out ...

Study demonstrated a 90% effectiveness of nirsevimab in preventing RSV-associated hospitalizations in infants, with a significant finding being the timely vaccination's role in offering protection.

Nirsevimab and the maternal vaccine for respiratory syncytial virus can reduce health care costs and productivity losses associated with RSV but lead to higher overall spending, according to ...